Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer-Reference-Cited by-同舟云学术

Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer

Published:2020-10-01 Issue:4 Volume:25 Page:445-453
ISSN:1472-8214
Container-title:Expert Opinion on Emerging Drugs
language:en
Short-container-title:Expert Opinion on Emerging Drugs

Author:

Lorusso Domenica¹²,Ceni Valentina³⁴,Muratore Margherita⁴⁵,Salutari Vanda⁴,Nero Camilla¹,Pietragalla Antonella¹,Ciccarone Francesca¹,Carbone Vittoria⁴,Daniele Gennaro¹,Scambia Giovanni¹²^ORCID

Affiliation:

1. Scientific Directorate Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy

2. Department of Life Science and Public Health, Catholic University of Sacred Heart Largo Agostino Gemelli, Rome, Italy

3. Department of Gynecology and Obstetrics, University of Parma, Via A. Gramsci, Parma, Italy

4. Department of Women and Child Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli, Rome, Italy

5. Department of Medical Oncology, University of Naples Federico II, Via S.Pansini, Naples, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14728214.2020.1836155

Reference58 articles.

1. Cancer statistics, 2018

2. A narrative review of neoadjuvant, HIPEC and maintenance treatment in ovarian and peritoneal serous cancer: current status

3. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

4. A Phase 3 Trial of Bevacizumab in Ovarian Cancer

5. OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dynamic Changes in Circulating Tumor Fraction as a Predictor of Real-World Clinical Outcomes in Solid Tumor Malignancy Patients Treated with Immunotherapy;Oncology and Therapy;2024-07-22

2. From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer;Journal of Ovarian Research;2024-02-12

3. NLRC5 overexpression in ovarian tumors remodels the tumor microenvironment and increases T-cell reactivity toward autologous tumor-associated antigens;Frontiers in Immunology;2024-01-03

4. NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer;International Journal of Biological Sciences;2024

5. The effectiveness of CA125 and HE4 as clinical prognostic markers in epithelial ovarian cancer patients with BRCA mutation;Journal of Gynecologic Oncology;2024